Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC

Written by Customer Service on March 4, 2023. Posted in Public Companies.

Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension Obesity was predictive of an enhanced response to lorundrostat with placebo-adjusted systolic BP reduction of 16.7 mmHg with 50mg once-daily dosing Additional clinical trial expected to begin in first half of 2023 RADNOR, Pa., March 04, 2023 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced positive data from the Target-HTN Phase 2 study that demonstrated clinically meaningful blood pressure reduction with once-daily dosing of lorundrostat at the American College of Cardiology’s 72nd Annual Scientific Session together with the World Congress of Cardiology...

<div>89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology</div>

89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology

Written by Customer Service on March 4, 2023. Posted in Public Companies.

– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless of their background lipid-modifying therapy status – SAN FRANCISCO, March 04, 2023 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the presentation of additional data from the Phase 2 ENTRIGUE trial of pegozafermin in patients with severe hypertriglyceridemia (SHTG) at the American College of Cardiology’s 72nd Annual Scientific Session & Expo Together with World Congress of Cardiology (ACC.23/WCC). The presentation featured results of a post hoc analysis exploring the effect of pegozafermin...

New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology

Written by Customer Service on March 4, 2023. Posted in Public Companies.

Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular ejection fraction (LVEF) range THE WOODLANDS, Texas, March 04, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational product sotagliflozin presented at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology in New Orleans, Louisiana. The “Time to Clinical Benefit of Sotagliflozin in People with Worsening Heart Failure in SOLOIST-WHF” post hoc analysis examined the timing of clinical benefit of sotagliflozin, defined as the first day post randomization when the hazard ratio (HR) for risk for...

Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients

Written by Customer Service on March 4, 2023. Posted in Public Companies.

Results Demonstrate Significant Reductions in LDL-C, hsCRP and Cardiovascular Risk in Patients Who Are Unable to Maximize or Tolerate a Statin – NEXLETOL Significantly Reduced Risk of Major Adverse Cardiovascular Events (MACE-4) and (MACE-3) by 13% (P=0.004) and 15% (P=0.006), Respectively, and Significantly Reduced Risk of Myocardial Infarction by 23% (P=0.002) and Coronary Revascularization by 19% (P=0.001) – – CLEAR Outcomes Demonstrated Superior Cardiovascular Outcomes Benefits Compared with Other Oral Non-Statin Therapies and Broader Outcomes Benefits in Primary and Secondary Prevention Compared with PCSK9 inhibitors Whose Outcomes Studies Were Limited to Only Secondary Prevention – – Detailed Results Simultaneously Published in the New England Journal of Medicine and Presented at ACC.23/WCC – – Anticipate Regulatory Filings in...

Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session

Written by Customer Service on March 4, 2023. Posted in Public Companies.

Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive HCM, Supporting Advancement to Phase 3 Additional Results from FOREST-HCM Demonstrate Long-Term Treatment with Aficamten for 48 Weeks is Well-Tolerated and Associated with Sustained Treatment Effect Company to Host Investor Event and Conference Call on March 6, 2023 at 8:30 AM Eastern Time SOUTH SAN FRANCISCO, Calif., March 04, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that positive results from Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), a Phase 2 clinical trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM), were presented at the American College of...

Lexicon Reveals “INTO THE DARK” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization

Written by Customer Service on March 4, 2023. Posted in Public Companies.

Into the Dark Into the Dark Campaign Image Emphasizes challenges faced by patients and clinicians within the first 30 days after discharge from a heart failure hospitalization Reinforces impact of rehospitalizations for heart failure patients and healthcare system Campaign launches at American College of Cardiology’s 72nd Annual Scientific Session Together with World Congress of Cardiology THE WOODLANDS, Texas, March 04, 2023 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the launch of a new disease awareness campaign focused on the cyclical nature of rehospitalizations for heart failure (HF) patients. The “INTO THE DARK” campaign focuses on the first 30 days following a heart failure patient’s hospitalization, which is the “danger zone” where the likelihood of poor outcomes, including rehospitalization,...

CORRECTION TO SUMMONS TO ROBIT PLC’S ANNUAL GENERAL MEETING 2023

Written by Customer Service on March 4, 2023. Posted in Public Companies.

ROBIT PLC STOCK EXCHANGE RELEASE 4 MARCH 2023 AT 12.00 P.M. CORRECTION TO SUMMONS TO ROBIT PLC’S ANNUAL GENERAL MEETING 2023 In summons to Robit Plc’s AGM 2023 published on 20 February 2023 at 12.00 pm, the Board of Directors proposed that a dividend of EUR 0.02 per share would be distributed for the 2022 financial period. The Board of Directors withdraws the proposal of payment of dividends and proposes to the AGM that EUR 0.02 per outstanding share be paid from the company’s distributable funds to the shareholders. The corrected summons to the AGM 2023 is as follows: The shareholders of Robit Plc are hereby invited to the Annual General Meeting to be held on Wednesday, 15 March 2023 from 2.00 pm onwards at Tampere Hall, address Yliopistonkatu 55, 33100, Tampere, Finland. The reception of registered participants and...

Blender Bites Receives Several US Purchase Orders and is Set to Unveil its Latest Functional Food Innovation at the Largest Natural Food Expo in the World¹

Written by Customer Service on March 4, 2023. Posted in Public Companies.

VANCOUVER, British Columbia, March 03, 2023 (GLOBE NEWSWIRE) — Blender Bites Ltd. (the “Company”, “Blender Bites” or “Blender”), (CSE: BITE, FWB: JL4, WKN: A3DMEJ), an award-winning Canadian company involved in the development and marketing of a line of premium, organic and plant-based pre-portioned frozen functional foods, is pleased to announce that it has received multiple purchase orders following its US tradeshow debut at the KeHE Summer show (the “Summer Show” or the “Tradeshow”), held Feb 7th and February 8th in Nashville, Tennessee, and also announces that it will unveil its latest functional food innovation – the 1-Step Frappé – at the upcoming Natural Products Expo West (“Expo West” or the “Expo”), next week. The Summer Show marked the kick off Blender Bites’ US launch with KeHE Distributors, LLC (“KeHE” the “Distributor”),...

Central 1 Reports 2022 Financial Results

Written by Customer Service on March 4, 2023. Posted in Earnings Releases And Operating Results.

VANCOUVER, British Columbia, March 03, 2023 (GLOBE NEWSWIRE) — Central 1 Credit Union (‘Central 1’ or ‘the organization’) reported a loss of $69.6 million for the year ended December 31, 2022, compared to a profit of $45.4 million in 2021. “Our 2022 financial story is reflective of the challenging market conditions during the year which has resulted in unrealized losses on our fixed income investments, but also stable performance in our core operations and revenue sources like interest margin, which remained strong,” said Sheila Vokey, Central 1 President & CEO. “Our Treasury team effectively managed Central 1’s portfolio which is predominately fixed income investments, supporting our Credit Union members with the provision of solid liquidity services. Our continued focus on enabling and supporting our members and clients...

Day: March 4, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice